Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 6;13(4):496.
doi: 10.3390/pharmaceutics13040496.

Updated View on Kidney Transplant from HCV-Infected Donors and DAAs

Fabrizio Fabrizi  1 , Roberta Cerutti  1 , Carlo M Alfieri  1   2 , Piergiorgio Messa  1   2
Affiliations
Review

Updated View on Kidney Transplant from HCV-Infected Donors and DAAs

Fabrizio Fabrizi et al. Pharmaceutics. .

Abstract

Background: The discrepancy between the number of potential available kidneys and the number of patients listed for kidney transplant continues to widen all over the world. The transplant of kidneys from hepatitis C virus (HCV)-infected donors into HCV naïve recipients has grown recently because of persistent kidney shortage and the availability of direct-acting antiviral agents. This strategy has the potential to reduce both waiting times for transplant and the risk of mortality in dialysis.

Aim: We made an extensive review of the scientific literature in order to review the efficacy and safety of kidney transplant from HCV-viremic donors into HCV naïve recipients who received early antiviral therapy with direct-acting antiviral agents (DAAs).

Results: Evidence has been rapidly accumulated on this topic and some reports have been published (n = 11 studies, n = 201 patients) over the last three years. Various combinations of DAAs were administered-elbasvir/grazoprevir (n = 38), glecaprevir/pibrentasvir (n = 110), and sofosbuvir-based regimens (n = 53). DAAs were initiated in a range between a few hours before renal transplant (RT) to a median of 76 days after RT. The sustained virological response (SVR) rate was between 97.5% and 100%. A few severe adverse events (SAEs) were noted including fibrosing cholestatic hepatitis (n = 3), raised serum aminotransferase levels (n = 11), and acute rejection (n = 7). It remains unclear whether the AEs were related to the transmission of HCV, the use of DAAs, or kidney transplant per se. It appears that the frequency of AEs was greater in those studies where DAAs were not given in the very early post-kidney transplant phase.

Conclusions: The evidence gathered to date encourages the expansion of the kidney donor pool with the adoption of HCV-infected donor organs. We suggest that kidney transplants from HCV-viremic kidneys into HCV-uninfected recipients should be made in the context of research protocols. Many of the studies reported above were externally funded and we need research generating "real-world" evidence. The recent availability of pangenotypic combinations of DAAs, which can be given even in patients with eGFR < 30/min/1.73 m2, will promote the notion that HCV-viremic donors are a significant resource for kidney transplant.

Keywords: HCV viremia; antiviral agents; hepatitis C; kidney donors; kidney transplant.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
HCV diagnostic assays and kidney transplant.
Figure 2
Figure 2
Antiviral therapy of HCV—a changing scenario.
See this image and copyright information in PMC

References

    1. Morales J., Fabrizi F. Hepatitis C and its impact on renal transplantation. Nat. Rev. Nephrol. 2015;2:172–182. doi: 10.1038/nrneph.2015.5. - DOI - PubMed
    1. Sise M., Chute D., Gustafson J., Wojciechowski D., Elias N., Chung R., Williams W. Transplantation of hepatitis C virus infected kidneys into hepatitis C virus uninfected recipients. Hemodialysis Int. 2018;2:S71–S80. doi: 10.1111/hdi.12650. - DOI - PubMed
    1. US Department of Health and Human Services. Health Resources and Services Administration (HRSA) Organ Procurement Transplant Network. National Data. [(accessed on 31 January 2021)]; Available online: https://optn.transplant.hrsa.gov/data/
    1. Fabrizi F., Martin P., Dixit V., Messa P. Meta-analysis of observational studies: Hepatitis C and survival after renal transplant. J. Viral. Hepat. 2014;2:314–324. doi: 10.1111/jvh.12148. - DOI - PubMed
    1. Kasuno K., Ono T., Matsumori A., Nogaki F., Kusano H., Watanabe H., Yodoi J., Muso E. Hepatitis C- associated tubulo interstitial injury. Am. J. Kidney Dis. 2003;2:767–775. doi: 10.1016/S0272-6386(03)00024-6. - DOI - PubMed